Adam Feuerstein weighs in (video) on the upcoming FDA decision on a lung inhaler from Alexza Pharmaceuticals (ALXA +0.8%), saying that an approval is "not a sure bet" and is too close to call. Trading volume in ALXA spiked higher after the biotech analyst's comments were distributed and digested, although shares only traced up moderately.